CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Hon'ble Prime Minister of India, Shri Narendra Modiji's inspiring presence at the Zydus Biotech Park28-11-2020
28-11-2020
Cadila Healthcare shares up 3% on plans to launch COVID-19 vaccine by March 2021
Zydus Cadila said it will apply for Phase 3 clinical trials of its experimental COVID-19 vaccine in December, and expects to launch it by March 2021.27-11-2020
PM to visit Covid-19 vaccine development sites
Sources say PM likely to visit Serum Institute in Pune, Zydus Cadila's facility in Ahmedabad on Saturday26-11-2020
Zydus Cadila's COVID-19 drug succeeds in Phase II Indian trials
Zydus Cadila's Pegylated Interferon alpha-2b, PegiHep, was originally approved for Hepatitis C and was launched in the Indian market in 2011; it was repurposed for treating moderate COVID-19 patients12-11-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus successfully completes Phase II clinical trials with Pegylated Interferon alpha-2b in India; the Company to start Phase III clinical trials12-11-2020
Accumulate Cadila Healthcare; target of Rs 497: Dolat Capital Market
Dolat Capital Market recommended accumulate rating on Cadila Healthcare with a target price of Rs 497 in its research report dated November 02, 2020.07-11-2020
Sell Cadila Healthcare; target of Rs 357: Prabhudas Lilladher
Prabhudas Lilladher is bearish on Cadila Healthcare has recommended sell rating on the stock with a target price of Rs 357 in its research report dated November 03, 2020.06-11-2020
Buy Cadila Healthcare: target of Rs 530: Sharekhan
Sharekhan is bullish on Cadila Healthcare recommended buy rating on the stock with a target price of Rs 530 in its research report dated November 03, 2020.05-11-2020
CADILA HEALTHCARE LTD. - 532321 - Intimation Regarding Issuance Of Commercial Papers.
In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that in terms of the guidelines issued by Reserve Bank of India, the Company has issued and placed for listing the Commercial Papers (CPs) amounting to Rs.625,00,00,000/- (Rupees Six Twenty Five Crores). This is to further inform that the above CPs are the part of limits of Rs.1,150/- Crores as approved by the Board of Directors of the Company at their meeting held on August 5, 2020. Please take the above information on record.04-11-2020
Covid Vaccine: Zydus Cadila completes phase-2 trial, to submit data in November
MD Sharvil Patel says company plans to begin phase-3 in December, upon approval, and expects to have final data by March-April 2021. The company plans to test the ZyCoV-D vaccine on about 15,000-20,000 people in Phase-3 and is hopeful of launching it in the first half of 2021.03-11-2020